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Abstract
Background. The number of terminal sialic acid and sulfonated N-acetylgalactosamine (SO3-GalNAc) on gonadotrophins in
serum varies during the menstrual cycle and changes at menopause, suggesting that gonadal steroids modify their oligo-
saccharide synthesis. Our objective was to determine the effects of 17b-oestradiol (E2) and a progestogen, norethisterone
acetate (NETA), on the sulfonation and sialylation of gonadotrophins in post-menopausal women.
Methods. Serum samples were obtained from eight post-menopausal women treated with 20 mg E2 implants every 6 months,
from four women who in addition were treated daily with 5 mg NETA orally for a 2-week period, and from four women who
got this NETA treatment during a 4-week period. Sera from 11 non-treated post-menopausal women served as a reference
group. The gonadotrophin serum concentrations, the number of SO3-GalNAc and sialic acid residues per serum luteinizing
hormone (LH) and follicle-stimulating hormone (FSH) molecule, and the distributions of molecules with 0-1-2-3-4 sulfonated
residues were measured.
Results. The E2-treated post-menopausal women had considerably less (P <0.001) sialic acid and slightly more (P <0.01) SO3-
GalNAc per serum LH and FSH molecule than the non-treated. Two weeks of NETA treatment increased the sulfonation of
LH (P <0.01) and FSH (P <0.05) concomitantly with decreased (P <0.05) sialylation of LH.
Conclusion. The primary effect of E2 treatment was a decrease in sialylation and, due to competition for the same substrate, a
secondary and consequentially minor increase in sulfonation of LH and FSH. The primary effect of the NETA therapy was an
increase in the sulfonation of LH and FSH concomitantly with secondary and consequentially decreases in sialylation of LH.
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Introduction
Human luteinizing hormone (LH) and follicle-
stimulating hormone ( FSH) are synthesized in the
pituitary and circulate in blood as individual spectra of
large numbers of different isoforms (1,2). The aspar-
agine-bound oligosaccharides, three on LH and four
on FSH, vary between isoforms with respect to the
number of terminal sialic acid and sulfonated
N-acetylgalactosamine (SO3-GalNAc) residues per
molecule (2,3). The composition of such LH and
FSH isoforms in serum varies during the menstrual
cycle, changes after menopause, and is different in
women with polycystic ovarian syndrome and in
healthy men compared with healthy women (2).
These results suggested that gonadal steroids, such
as oestrogen, progesterone, and androgen, modify the
enzyme activity in the sialylation and/or the sulfona-
tion pathways of the gonadotrophin synthesis in the
human pituitary.
The effect of gonadal steroids on gonadotrophin
glycosylation was extensively studied in animal exp-
eriments in which LH and FSH were extracted from
the pituitaries (4). It was concluded that oestradiol
reduces while testosterone increases the sialylation. In
the human, similar studies have been restricted to
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DOI: 10.3109/03009730903573253analyses of FSH and LH in blood. Effects of gonadal
steroids on the synthesis of human gonadotrophin
isoforms have been observed as changes in net charge
of the molecules (5–15). Both the sialic acid and the
sulfonated GalNAc residues are negatively charged
and determine the anionic character of the oligosac-
charides and thereby the net charge of the gonado-
trophin molecules. These two negatively charged
residues have biological implications, as the number
of sialic acid and sulfonated GalNAc residues on
human LH and FSH determines their clearance from
thecirculation.MoresulfonatedGalNAcpermolecule
decreases and more sialic acid per molecule increases
the half-life of human LH and FSH in blood (16,17).
Administration of 17b-oestradiol (E2) implants in
post-menopausal women was shown to counteract
the formation of the more anionic (acidic) forms of
both LH and FSH normally secreted in these women
(8). The effect of a progestogen, norethisterone
acetate, on the net charge of the isoforms in the E2-
treated women was signiﬁcant and time-related (11).
More anionic forms appeared in the circulation
during the ﬁrst 2 weeks of progestogen treatment,
while during the following 2 weeks the isoforms
became more cationic (basic) again. The objective
of the present study was to determine to what
extent these effects of E2 and norethisterone acetate
(NETA) on the molecular net charge were due to
changes in sialic acid and/or sulfonated GalNAc
residues on the gonadotrophins. The average num-
ber of sialic acid and sulfonated GalNAc residues
per molecule of LH and FSH in serum was esti-
mated with a method based on neuraminidase
treatment, electrophoresis, and immunoﬂuorometric
hormone assays (2). In addition, the distributions
of isoforms with zero to four SO3-GalNAc resi-
dues per molecule were measured. The results
were compared with those of 11 non-treated post-
menopausal women.
Material and methods
Subjects, serum samples, and experimental design
Serum samples were analysed from eight women,
mean age 65 years (range 50–79), treated with
20 mg E2 implanted subcutaneous in pellets (Orga-
non Laboratories Ltd, UK) every 6 months (group:
E2-implant). The samples were obtained 4–18 (mean
15.6) weeks after the insertion of the E2 implant, and
the mean E2 level was 352 pmol/L (range 270–420).
Serum samples were also analysed from four
women, mean age 64 years (range 50–79), who in
addition to this E2 therapy for a mean of 11 weeks
(range 6–20) were treated for 2 weeks with oral
therapy of 5 mg NETA (Primolut-Nor, Scherman
AG, Germany) daily (group: E2+2wNETA). Their
mean E2 level was 286 pmol/L (range 230–320).
Serum samples were also analysed from four women
after 4 weeks of the NETA treatment (group:
E2+4wNETA), mean age 58 years (range 50–69),
with a mean of 13 weeks (range 8–22) after insertion
of the E2 implant. Their mean E2 level was 338
pmol/L (range 310–370). Two patients, A and B,
participated in all three treatment groups. Patient A
was treated twice with NETA, at 4 and at 18 weeks
after insertion of the E2 implant, and serum
samples were obtained before and after 2 and 4
weeks of NETA treatment. All the women had
been hysterectomized and experienced meno-
pausal symptoms before the ﬁrst E2 implant, and
they had been treated for a mean of 12 years (range
1.5–21). Serum specimens from 11 non-treated
post-menopausal women, mean age 65 years
(range 61–77), constituted a reference group. No
individual had the common variant form of LH
(17–19). The study was approved by the local
Ethics Committee.
Analytical methods
The study comprises a total of 3,000 gonadotrophin
assays on the 30 sera and includes neuraminidase
treatment and two electrophoreses of all sera and
analyses to exclude the occurrence of the common
genetic variant form of LH (17–19) among the
patients. The concentrations of LH and FSH in
serum samples and in 200 mL of fractions eluted
after 0.10% agarose suspension electrophoresis
were measured using sandwich ﬂuoroimmunoassays
(Delﬁa, PerkinElmer-Wallac Oy, Turku, Finland), as
previously described (20). Gonadotrophin values
were expressed in IU/L using the International Stan-
dards for pituitary LH (80/552) and FSH (94/632) as
reference standards. The detection limits in
serum were 0.02 IU/L, and the interassay coefﬁ-
cient of variation (CV) was less than 3% for both
hormones.
The average number of sialic acid and sulfonated
GalNAc residues per LH and FSH molecule and
the distribution of molecules with zero to four
sulfonated GalNAc were estimated, as previously
described (2). The method is based upon the obser-
vation by Green and Baenziger (3) that these two
negatively charged residues determine the anionic
character of N-linked oligosaccharides on the
gonadotrophins. All serum samples were analysed
before and after neuraminidase treatment with an
electrophoretic technique using a 0.10% agarose sus-
pension in veronal buffer at pH 8.7 (2,21).
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Results are presented as mean values ± SEM. The
mean values of the two serum samples of patient A
in each treatment group were used in the statis-
tical analyses. Statistical comparisons were made
with non-parametric Mann-Whitney test. Relation-
ships were identiﬁed by calculating Spearman’s rs.
A P-value <0.05 was considered to be signiﬁcantly
different.
Results
Effects of E2 implants
The serum concentrations of FSH and LH and
the number of sialic acid and sulfonated GalNAc
residues per molecule in the non-treated and the
E2-implant groups are given in Table I. The gonad-
otrophin serum levels of the E2-implant group were
signiﬁcantly lower (P <0.01 for LH and <0.001 for
FSH) than in the reference group of non-treated post-
menopausal women. The number of sialic acid resi-
dues per molecule was signiﬁcantly (P <0.001) lower
in the E2-implant than in the non-treated group of
both LH and FSH. The corresponding number of
sulfonated GalNAc residues was increased (P <0.01)
on both gonadotrophins in the E2-implant group.
The decrease in sialic acid was larger than the
increase in sulfonated residues resulting in decreased
(P <0.001) total number of negatively charged resi-
dues per molecule on both LH (minus 0.34 ± 0.04)
and FSH (minus 0.63 ± 0.11) in the E2-implant group
compared with the non-treated group of women. The
Table I. Sialic acid and sulfonated GalNAc residues per LH and FSH molecule in serum and frequency of isoforms with zero to four
sulfonated GalNAc residues. Four groups of post-menopausal women: non-treated, treated with 20 mg E2 implant, and, in addition to E2, with
2 and 4 weeks of oral therapy with 5 mg NETA daily.
Group Non-treated E2-implant E2+2wNETA E2+4wNETA
Number of women 11 8 4 4
LH; mean ± SEM
Serum level (IU/L) 24.4 ± 1.80 10.2 ± 2.21
b 3.08 ± 0.56
a 1.48 ± 0.48
a,d
Sialic acid residues 2.64 ± 0.04 2.14 ± 0.04
c 1.86 ± 0.04
a 1.57 ± 0.06
a,d
Sulfonated GalNAc 0.99 ± 0.04 1.15 ± 0.03
b 1.64 ± 0.03
b 1.80 ± 0.03
a,d
Ratio Sial./Sulf. 2.70 ± 0.11 1.87 ± 0.07
c 1.14 ± 0.04
b 0.87 ± 0.04
a,d
Negatively charged residues 3.64 ± 0.03 3.29 ± 0.03
c 3.50 ± 0.02
b 3.37 ± 0.05
Zero SO3-GalNAc (%) 30.7 ± 2.44 28.1 ± 0.90 14.2 ± 2.62
b 6.04 ± 2.43
d
One SO3-GalNAc (%) 46.9 ± 3.54 40.3 ± 2.08 30.8 ± 2.91 28.6 ± 2.96
Two SO3-GalNAc (%) 15.9 ± 2.57 21.5 ± 2.40 37.5 ± 2.26
b 45.5 ± 11.2
d
Three SO3-GalNAc (%) 5.80 ± 1.40 8.68 ± 2.00 14.4 ± 1.65 18.9 ± 6.77
Four SO3-GalNAc (%) 0.79 ± 0.36 1.42 ± 0.65 3.82 ± 1.15 0.91 ± 0.77
Two to four SO3-GalNAc (%) 22.4 ± 1.92 31.6 ± 1.89 55.7 ± 1.51
b 65.3 ± 4.58
a,d
FSH; mean ± SEM
Serum level (IU/L) 56.5 ± 4.01 10.4 ± 2.63
c 4.20 ± 1.31 2.21 ± 0.41
a,d
Sialic acid residues 7.55 ± 0.03 6.53 ± 0.11
c 6.68 ± 0.07 6.17 ± 0.10
a
Sulfonated GalNAc 0.22 ± 0.03 0.39 ± 0.03
b 0.58 ± 0.04
a 0.80 ± 2.73
a,d
Ratio Sial./Sulf. 44.5 ± 9.98 17.4 ± 1.49
c 11.7 ± 1.0 7.71 ± 0.39
a,d
Negatively charged residues 7.55 ± 0.03 6.92 ± 0.12
c 7.26 ± 0.05
a 7.00 ± 0.06
a
Zero SO3-GalNAc (%) 86.6 ± 2.08 74.1 ± 2.34
b 63.6 ± 2.90
a 48.6 ± 2.46
a,d
One SO3-GalNAc (%) 4.93 ± 1.17 13.2 ± 2.49
b 15.1 ± 1.39 24.0 ± 3.31
Two SO3-GalNAc (%) 8.07 ± 1.03 12.1 ± 1.32
a 20.8 ± 2.11
b 26.3 ± 1.15
a,d
Two to four SO3-GalNAc (%) 8.45 ± 1.00 12.8 ± 1.14
a 21.3 ± 1.63
b 27.4 ± 1.62
a,d
Statistical comparisons with non-parametric Mann-Whitney test.
aP <0.05 versus preceding group.
bP <0.01 versus preceding group.
cP <0.001 versus preceding group.
dP <0.01 versus E2-implant group.
Effects of E2 and NETA on FSH and LH isoforms 99ratio of sialic acid to sulfonated GalNAc residues per
molecule was lower (P <0.001) in the E2-implant
group than in the non-treated women: for LH 1.9
versus 2.7, and for FSH 17 versus 44 (Table I).
Effects of NETA in three individual studies
Sera from three individual studies with samples taken
before and after 2 and 4 weeks of NETA treatment
were analysed. Two of these were from one patient A,
starting the NETA treatment at weeks 4 and 18 after
insertion of the E2 implant, and the third from
patient B with start of NETA treatment at E2 implant
week 18. The changes in sialic acid and sulfonated
residues and in total number of negatively charged
residues are shown for LH in Figure 1 and for FSH
in Figure 2.
There was in all three cases an increase in the
number of sulfonated residues on LH after 2 weeks
of treatment which was larger than the decrease in
sialic acid residues. Therefore, the net effect was an
increase in the total number of negatively charged
residues. During the following 2 weeks of treatment
the number of sulfonated residues further increased.
During this period there was a more dramatic
decrease in sialic acid residues. This decrease was
larger than the increase in sulfonated residues result-
ing in a change of the total number of negatively
charged residues back to values close to those before
treatment with NETA.
FSH showed a similar change in sulfonated resi-
dues but less pronounced compared to LH. The
changes in sialic acid during 2 weeks of NETA ther-
apy varied from a slight decrease to a slight increase,
and the net charge became more negative in all three
cases. During the next 2 weeks of NETA treatment
the contents of sialic acid on FSH decreased more
than the number of sulfonated residues increased.
The net effect was a decrease in negatively charged
groups, and the charge was similar to that at the start
of treatment.
Effects of NETA treatment—groups compared
The serum concentrations of LH and FSH and the
number of sialic acid and sulfonated GalNAc residues
per molecule in the E2-implant, E2+2wNETA, and
E2+4wNETA groups are given in Table I. The serum
gonadotrophin concentrations decreased signiﬁcantly
(P <0.01) after 4 weeks of NETA treatment. The
mean levels of LH and FSH were suppressed to 6%
and 4%, respectively, of those of the non-treated post-
menopausal women.
The change in sialic acid and sulfonated GalNAc
residues per LH and FSH molecule after 2 and
4 weeks of NETA treatment is illustrated in Figure 3.
The number of sulfonated residues increased for both
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Figure 1. Relationship between LH concentration and changes in
the number of sialic acid (open star) and sulfonated (ﬁlled circle)
residues and negatively charged residues (ﬁlled square) on the
oligosaccharides per LH molecule after 2 and 4 weeks of NETA
therapy in two E2-implant-treated post-menopausal women. The
average numbers of sialic acid (SA
-) and sulfonated (SO3
-) residues
per serum LH molecule at the start of NETA treatment are given
(w = weeks).
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FSH. The number of sialic acid residues on LH
decreased during the ﬁrst 2 weeks of NETA treatment
and continued to decrease during the second 2 weeks
of treatment. The number of sialic acid residues per
FSH molecule was unchanged after 2 weeks of NETA
treatment and decreased during the second 2 weeks of
treatment. The net effect of the ﬁrst 2 weeks of
treatment with NETA was an increase in the total
number of negatively charged residues per molecule
which was 0.20 ± 0.05 (P <0.01) for LH and
0.34 ± 0.17 (P <0.05) for FSH. During the last
2 weeks of NETA treatment the total number of
negatively charged residues decreased with
0.13 ± 0.05 (P = 0.05) on LH and with 0.28 ± 0.09
(P <0.05) on FSH.
The ratios of sialic acid to sulfonated residues on
LH and FSH during the NETA treatment are
given in Table I. The ratios decreased signiﬁcantly
(P <0.01) after 4 weeks to 0.87 for LH and to 7.71 for
FSH.
Sialic acid and SO3-GalNAc residues per molecule
versus serum levels of LH and FSH
The relationships between the degrees of sialylation
and sulfonation of the gonadotrophins and their
serum levels are shown in Figure 4. The ﬁgure illus-
trates that the relationships between the number
of sulfonated GalNAc per molecule and the serum
levels of LH and FSH are negative and that the
corresponding relationships for sialic acid are
positive. The estimated coefﬁcients of correlation
(Spearman’s rs) were for LH concentration versus
sulfonated GalNAc residues 0.73 and versus sialic
acid residues 0.86, and the corresponding values for
FSH were 0.82 and 0.83, respectively (P <0.0001
for all rs-values; n = 27).
Distributions of LH and FSH molecules with different
number of SO3-GalNAc residues
The distributions of LH and FSH isoforms with
different number of sulfonated GalNAc residues
per molecule in serum are given as mean values in
per cent of total in Table I. The distributions of LH
isoforms were similar for the non-treated and the E2-
implant-treated groups. During the NETA treatment
there was a decrease (P <0.01) of the non-sulfonated
LH isoforms from 28% to 6% and an increase
(P <0.01) of the isoforms with two to four sulfonated
GalNAc residues from 32% to 65%.
The frequency of non-sulfonated isoforms of FSH
decreased (P <0.01) from 87% in the non-treated to
74% in the E2-implant group. There was then a
further decrease (P <0.01) to 49% after 4 weeks of
the NETA treatment. The frequency of FSH isoforms
with two to four sulfonated residues increased
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Figure 2. Relationship between FSH concentration and changes in
the number of sialic acid (open star) and sulfonated (ﬁlled circle)
residues and negatively charged residues (ﬁlled square) on the
oligosaccharides per FSH molecule after 2 and 4 weeks of
NETA therapy in two E2-implant-treated post-menopausal women.
The average numbers of sialic acid (SA
-) and sulfonated (SO3
-)
residues per serum FSH molecule at the start of NETA treatment
are given (w = weeks).
Effects of E2 and NETA on FSH and LH isoforms 101(P <0.01) from 8.4% in the non-treated to 27% in the
E2+4wNETA group.
Discussion
In this study we have examined the effect of oestradiol
and of the addition of a progestogen, NETA, on the
number of sialic acid and sulfonated GalNAc residues
on serum LH and FSH in post-menopausal women.
Our results indicate that both the oestradiol and the
progestogen modulate the sulfonation and the sialyla-
tion of the oligosaccharides and suggest that oestra-
diol predominantly inhibits the sialylation pathway
while the main effect of the progestogen is an
enhancement of the sulfonation pathway.
The biochemical events leading to terminal
sialylation or sulfonation of LH have been reviewed
by Baenziger (22). The sulfonation pathway leading
to terminal SO3-4GalNAc is ﬁrst regulated by a
peptide-speciﬁc b1-4GalNAc-transferase adding Gal-
NAc to the subterminal GlcNAc residue on the bian-
tennary glycan chains. This b1-4 linked GalNAc
moiety is then sulfonated by a sulfotransferase. This
sulfonation pathway occurs in competition with a
b1-4galactosyltransferase adding galactose to the
same subterminal GlcNAc in a sialylation pathway
leading to terminal sialic acid. A Pro-Leu-Arg tripep-
tide motif on the b-subunit of LH and a cluster of
cationic amino acids (Pro-Leu-Arg-Ser-Lys-Lys)
within an a-helix on the a-subunit are recognized
by the peptide-speciﬁc b1-4GalNAc-transferase lead-
ing to a considerably increased rate of GalNAc
transfer to the LH molecule (23,24). The tripeptide
motif on b-LH is not present on the FSH b-subunit,
and the a-subunit recognition motif is thought to
be masked by the b-subunit of FSH. Therefore, the
activityofthepeptide-speciﬁcb1-4GalNAc-transferase
is low, and the sialylation pathway dominates on
FSH (22).
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102 L. Wide et al.The E2-treated post-menopausal women had con-
siderably less (P <0.001) sialylated and slightly more
sulfonated isoforms than the non-treated. This is
interpreted as an inhibition of the sialylation pathway
with the consequence that more of the substrate, the
subterminal GlcNAc, is available for the sulfonation
pathway. This seems to be a more likely explanation
to the slightly higher levels of sulfonated GalNAc in
the E2-implant group than the alternative: a direct
enhancement of the sulfonation pathway.
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Effects of E2 and NETA on FSH and LH isoforms 103Our observations on the effects of oestradiol are in
agreement with those of two animal studies in which
the oestradiol effects on the enzymes involved in the
glycosylation of the oligosaccharides were investigated
(25,26). The effect of oestrogen on one of the pitu-
itary enzymes in the sialylation pathway, that adds
sialic acid to galactose, was investigated by Damián-
Matsumura et al. (26) in the female rat. Administra-
tion of oestradiol benzoate to castrated female rats was
shown to signiﬁcantly reduce the mRNA level for
the pituitary a2,3-sialyltranferase. Dharmesh and
Baenziger (25) studied the effect of oestrogen on
the enzymes in the sulfonation pathway. They showed
that in the female rat the levels of GalNAc-transferase
and sulfotransferase in the pituitary were regulated by
oestrogen in a similar manner as their substrate, the
LH molecules. The proportion of oligosaccharides
terminating with sulfonated GalNAc remained
constant.
During the ﬁrst 2 weeks of the progestogen therapy
the sulfonation of both LH and FSH increased. The
total number of negatively charged residues increased
signiﬁcantly during this period. We interpret the
effect of the progestogen as an enhancement of the
enzyme activities along the sulfonation pathway.
A consequence of an increased activity in the sulfo-
nation pathway during the progestogen therapy is a
decrease in available subterminal GlcNAc, the sub-
strate for the galactosyltransferase, for the sialylation
pathway. This is a likely explanation to the decreased
sialylation of LH during the ﬁrst 2 weeks of NETA
therapy.
The remarkable time-related change in the net
charge of the gonadotrophins between 2 and 4 weeks
of NETA therapy, as previously reported (11), can
now be explained by the ﬁndings of the present
study. During this prolonged period of NETA ther-
apy, the number of sialic acid residues per molecule
of LH and FSH decreased more than the number
of sulfonated residues increased, leading to a dec-
rease in negatively charged residues on the hor-
mones. We suggest two possible explanations to
this ‘oestrogen-like’ effect during the last 2 weeks of
NETA treatment. A decreased sex hormone bind-
ing globulin (SHBG) level induced by the NETA
therapy is expected to lead to more of free E2 in
the circulation (11,27). An alternative possible
explanation is a conversion of norethisterone acetate
to ethinyl oestradiol similar to that reported for
norethindrone acetate (28).
The increased sulfonation of both LH and FSH
found during the luteal phase of the cycle was sug-
gested to be an effect of progesterone on the enzymes
in the sulfonation pathway (2). This hypothesis is
further supported in the present study by the
increased number of sulfonated residues per LH
and FSH molecule during the progestogen therapy.
Women with raised androgen levels, as in the
polycystic ovarian syndrome (PCOS), had decreased
sulfonation and increased sialylation of LH and FSH
when compared with healthy women in the follicular
phase (2). These effects of androgens on the glyco-
sylation were thus opposite to those found for the
progestogen NETA in the present study.
There is a general agreement that the oligosaccha-
ride heterogeneity on the gonadotrophin molecules
has some kind of physiological signiﬁcance in the
human (29–31). In this study, the oligosaccharide
variation most likely played an important physio-
logical role when the serum levels of the gonado-
trophins decreased during the oestradiol and
NETA treatments to mean levels of 6.1% for LH
and 3.9% for FSH compared with the non-treated
group. The serum level is determined by the secretion
rate and the metabolic clearance rate of the gonado-
trophin isoforms. More sulfonated residues and
fewer sialic acid residues per molecule were associated
(P <0.0001) with lower serum levels of the gonado-
trophins. More sulfonated and less sialylated gonado-
trophins disappear faster from the human circulation
(16,17). It seems likely that the increased sulfonation
and decreased sialylation of the gonadotrophins sub-
stantially contributed to the decreased serum levels
during both the oestradiol and the progestogen
therapies.
Serum LH isoforms with two or more sulfonated
GalNAc residues disappear considerably faster from
the circulation than those with zero or one (16,17).
This was thought to be due to a rapid removal from
the circulation by a human hepatic receptor speciﬁc
for SO3-4GalNAcb1,4GlcNAcb1,2Mana structure
similar to that found in rodents (32,33). The fre-
quency of LH isoforms with two to four SO3-GalNAc
residues in the E2-implant group was 31.6%, a ﬁgure
close to that (32%) in younger women at follicular
phase (2). During the NETA therapy the frequency
increased after 2 and 4 weeks to 56% and 65%,
respectively. These values are considerably higher
than the 37% reported for the luteal phase of the
cycle (2), and the difference may be explained by the
progestogen preparation, the dose, and/or the long E2
implant treatment of the post-menopausal women.
The high frequency of more sulfonated residues is
expected to lead to a rapid disappearance of these LH
isoforms from the circulation and explain the very low
LH serum levels during the NETA treatment in this
and in the previous report (11).
The sialic acid residues constitute 96.2% of the
negatively charged residues on the oligosaccharides
on FSH extracted from human pituitaries taken at
104 L. Wide et al.autopsy (3). The corresponding mean percentage of
sialic acid residues on serum FSH from men and post-
menopausal women was 97.2% (2). As the degree of
sulfonation of FSH is very low, large changes in
charge to less anionic (acidic) FSH isoforms during
oestrogen treatment of both men and women have
been interpreted as decreases in the sialic acid con-
tents (5–15). We can conﬁrm this interpretation with
the results of the present study. On the other hand, a
change in charge to more anionic FSH isoforms
should be interpreted with caution as it could be
due to an increase in sulfonated and/or sialic acid
residues.
In this study we have examined the effect of oes-
tradiol and ofa progestogen,NETA,on the sialylation
and the sulfonation of LH and FSH in E2-treated
post-menopausal women. The report indicates that
the primary effect of the E2 treatment was a decrease
in the sialylation and, due to competition for the same
substrate, secondarily and consequentially a minor
increase in the sulfonation of FSH and LH. The effect
of 2 weeks of treatment with NETA was primarily an
activation of the sulfonation pathway during the
synthesis of LH and FSH and, consequentially, also
a minor decrease in the sialylation pathway of LH.
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